

RISANKIZUMAB solution for injection (Skyrizi® ▼) for psoriatic arthritis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of RISANKIZUMAB solution for injection (Skyrizi® ▼) for psoriatic arthritis.

GREY

Risankizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of PsA should continue to follow national guidance, local pathways and local formulary choices.

- > NICE Guideline [NG65]: [Spondyloarthritis in over 16s: diagnosis and management](#) (last updated 02 June 2017)
- > Pan Mersey APC Pathway: [PSORIATIC ARTHRITIS and PERIPHERAL SPONDYLOARTHROPATHY: high cost drugs pathway](#) (last updated 23 September 2020)
- > Pan Mersey APC Formulary: Chapter 10.01.03 [Drugs which suppress the rheumatic disease process](#)

References

1. AbbVie Ltd. Summary of Product Characteristics; [Skyrizi 150 mg solution for injection in pre-filled pen \(Great Britain\)](#), 18 November 2021. Accessed online 17 December 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.